Current drugs for depression target the regulatory process for neurotransmitters, and while effective in some cases, do not appear to work in other cases.
Recent findings suggest that synucleins, a family of small proteins in the brain, are key players in the management of neurotransmitters — specifically, alpha- and gamma-synuclein. Additionally, researchers have found elevated levels of gamma-synuclein in the brains of both depressed animals and humans.
In a study presented at the 39th annual meeting of the Society for Neuroscience, Georgetown University Medical Center researchers observed increased depressive-like behavior in mice where gamma-synuclein acts alone to regulate neurotransmitters, confirming earlier studies by this group.
“These findings show the importance of, and clarify a functional role for, gamma synuclein in depression and may provide new therapeutic targets in treatment of this disease,” says Adam Oaks, a student researcher in the Laboratory of Molecular Neurochemistry at GUMC. “Understanding how current therapies work with the synucleins is important because the drugs don’t work for all patients, and some are associated with side effects including an increased risk of suicide.”
The study was funded by grants from the National Institutes of Health. A provision patent application has been filed by Georgetown University related to the technology described in this paper, on which Anita Sidhu, one of the authors, is an inventor.
About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through Georgetown’s affiliation with MedStar Health). GUMC’s mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis – or “care of the whole person.” The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university’s sponsored research funding.
Karen Mallet (media only)